Sita

Sita

sitagliptin

Manufacturer:

CCL Pharma

Distributor:

Manawhari
Concise Prescribing Info
Contents
Sitagliptin
Indications/Uses
As adjunct to diet & exercise to improve glycaemic control in patients w/ type 2 DM as monotherapy. Combination therapy w/ metformin or PPARγ agonist (ie, thiazolidinediones) as initial therapy or when diet & exercise do not provide adequate glycaemic control. Combination w/ sulfonylurea when treatment w/ the single agent alone does not provide adequate glycaemic control. Combination w/ metformin & a sulfonylurea or metformin & PPARγ agonist when dual therapy w/ these agents, w/ diet & exercise, does not provide adequate glycaemic control.
Dosage/Direction for Use
Monotherapy or as combination therapy w/ metformin, sulfonylurea, PPARγ agonist, metformin + sulfonylurea, metformin + PPARγ agonist 100 mg once daily. Patients w/ renal insufficiency: Moderate renal insufficiency (CrCl ≥30 to <50 mL/min) 50 mg once daily; severe renal insufficiency (CrCl <30 mL/min) or w/ end-stage renal requiring haemodialysis or peritoneal dialysis 25 mg once daily.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be used in patients w/ type 1 diabetes or treatment of diabetic ketoacidosis. Discontinue use if hypersensitivity reactions eg, anaphylaxis, angioedema & exfoliative skin conditions including Stevens-Johnson syndrome occur; or pancreatitis is suspected. Patients w/ renal insufficiency. Lower dosages are recommended in moderate & severe renal insufficiency, in ESRD patients requiring hemodialysis or peritoneal dialysis. Lower dose of sulfonylurea to reduce risk of sulfonylurea-induced hypoglycaemia. Pregnancy & lactation. Childn <18 yr. Elderly.   
Adverse Reactions
Abdominal pain, nausea, vomiting & diarrhea. Hypoglycemia; headache, upper resp tract infection, cough, fungal skin infection, peripheral oedema; dyspepsia, flatulence; asymptomatic decreased blood glucose.
Drug Interactions
Monitor patients receiving digoxin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Sita FC tab 100 mg
Packing/Price
10 × 7's
Form
Sita FC tab 50 mg
Packing/Price
2 × 7's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in